

Amendments to the claims:

Please cancel claims 6-9 and 12-20 without prejudice to their renewal in a related patent application.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method of treating neointimal hyperplasia in a subject in need thereof, comprising administering an interleukin-1 (IL-1) antagonist to the subject such that neointimal hyperplasia is treated, wherein the IL-1 antagonist is an IL-1 trap comprising an extracellular domain of human IL-1 receptor, an extracellular domain of human IL-1 accessory protein, and a multimerizing component.
2. (original) The method of claim 1, wherein the neointinal hyperplasia is restenosis.
3. (original) The method of claim 1, wherein the neointimal hyperplasia is atherosclerosis.
4. (original) The method of claim 1, wherein the neointimal hyperplasia is vascular access dysfunction.
5. (original) The method of claim 1, wherein the neointimal hyperplasia is caused by surgical stenting, angioplasty, or vascular grafting.
- 6-9. (canceled)
10. (original) The method of claim 1, wherein the subject is a human.
11. (currently amended) The method of claim 1, wherein the administration is ~~subcutaneous, intramuscular, intranasal, intraarterial, or intravenous, topical, transvaginal, transdermal, transanal administration or oral routes of administration.~~
- 12-20. (canceled)